3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
233
Head and Neck Neoplasms
150
Squamous Cell Carcinoma of Head and Neck
136
Stomach Neoplasms
117
Lung Neoplasms
109
Esophageal Neoplasms
90
Uterine Cervical Neoplasms
72
Neoplasms
67
Urinary Bladder Neoplasms
56
Breast Neoplasms
48
Ovarian Neoplasms
46
Esophageal Squamous Cell Carcinoma
45
Pancreatic Neoplasms
44
Small Cell Lung Carcinoma
42
Neoplasm Metastasis
40
Adenocarcinoma Of Esophagus
38
Carcinoma, Squamous Cell
33
Carcinoma, Ovarian Epithelial
32
Mesothelioma, Malignant
30
Parkinson Disease 4, Autosomal Dominant Lewy Body
28
Lymphoma
28
Adenocarcinoma of Lung
25
Sarcoma
24
Cholangiocarcinoma
24
Nasopharyngeal Carcinoma
22
Carcinoma
22
Unspecified Adult Solid Tumor, Protocol Specific
21
Neuroblastoma
21
Gallbladder Neoplasms
21
Central Nervous System Neoplasms
21
Interventions
ganitumab
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
dalotuzumab
1
conatumumab
1
cixutumumab
1
Sorafenib
1
Receptor Protein-Tyrosine Kinases
1
Paclitaxel
1
Lapatinib
1
Istiratumab
1
Cisplatin
1
Capecitabine
1
BIIB022
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Insulin-Like Growth Factor I, Resistance To
×
Cisplatin
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled